Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization Strategies for Blood Transfusion in Hemorrhagic Shock
NCT07129031Phase 3Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Modality
- Tissue Cells
- Countries
- 1
01
Overview
A Phase 3 trial of low-titer group O whole blood in hemorrhagic shock, sponsored by Xijing Hospital. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
low-titer group O whole blood
03
Conditions
hemorrhagic shock
Beyond the preview
Go deeper on NCT07129031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07129031.